Bergabunglah dengan Buletin Kami
Bergabunglah dengan daftar pelanggan kami untuk mendapatkan artikel terkini, update dan penawaran khusus langsung di kotak masuk Anda
At AGBT’s close, Julianna LeMieux and Kevin Davies discuss announcements from th...
Researchers have developed a new form of highly sensitive CAR T cells, known as ...
In Phase I, 77 pretreated patients with advanced solid tumors harboring a TP53 Y...
City Therapeutics launched its first clinical program last fall, when it began a...
Conventional farming practices often rely on the use of nitrogenous fertilizers ...
In this webinar, The post De-Risking RNA Therapeutics with High-Resolution Sequ...
Amid growing demand for metabolic treatments, Novo Nordisk and Vivtex have struc...
The Medicare drug price “negotiation” process has entered its third year, with s...
Apheris's ADMET Network will combine proprietary datasets in a privacy-preservin...
VIR-5500 is a Phase I dual-masked T-cell engager (TCE) candidate designed to tar...
Using a massively parallel reporter assay to test more than 220,000 DNA variants...
Proposals to let decisions by other countries control American drug prices are i...
The inaugural Biotechnology Innovation Organization (BIO) Investment and Growth ...
The Valley of Death is a healthcare crisis, but the nonprofit, Music Beats Cance...
MassID expands the number of metabolites that can be identified and used for dow...
Reporting from AGBT in Orlando, Julianna LeMieux reviews key announcements inclu...